Evaluation of miRNA-146a, miRNA-34a, and pro-inflammatory cytokines as a potential early indicators for type 1 diabetes mellitus
Authors:
- Amal A. MohamedAMAmal A. Mohamed
- Gamil M. AbdallahGAGamil M. Abdallah
- Ibrahim T. IbrahimIIIbrahim T. Ibrahim
- Nada S. AliNANada S. Ali
- Mona A. HusseinMHMona A. Hussein
- Ghada Maher ThabetGTGhada Maher Thabet
- Omar M. AzzamOAOmar M. Azzam
- Amira Yones MohamedAMAmira Yones Mohamed
- Maysa I. FarghlyMFMaysa I. Farghly
- Eman Al HussainEHEman Al Hussain
- Samia S. AlkhalilSASamia S. Alkhalil
- Alaa Aly Mohamed AbouaggourAAAlaa Aly Mohamed Abouaggour
Open Access
- 1 December 2024
- journal article
- research article
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (4) , 1249-1256
Abstract
Type I diabetes mellitus (T1DM) is one of the most common chronic autoimmune diseases worldwide. miRNAs are a class of small non-coding RNA molecules that have been linked to immune system functions, β-cell metabolism, proliferation, and death, all of which contribute to pathogenesis of TIDM. Dysregulated miRNAs have been identified in Egyptian TIDM patients. Several miRNAs were profiled in Egyptian TIDM patients to determine whether they can be used as molecular biomarkers for T1DM. The relationship between the investigated miRNAs and pro-inflammatory cytokines (TNF-α and IL-6) has also been evaluated in the development of TIDM, in addition to the creation of a proposed model for TIDM prediction. Case-control study included 177 Egyptian patients with confirmed type I diabetes mellitus and 177 healthy individuals. MiRNA-34 and miRNA-146 were detected in serum samples using real-time PCR, whereas TNF-α and IL-6 levels were assessed using ELIZA. Patients with TIDM showed a significant decrease in the expression of miRNA-146, with a cut-off value ≤ 3.3, 48 % specificity, and 92.1 % sensitivity, whereas miRNA-34 had the highest sensitivity (95.5 %) and specificity (97.2 %) for differentiating diabetic patients from controls. Furthermore, other diagnostic proinflammatory markers showed lower sensitivity and specificity. Serum levels of miRNA-34a, miRNA-146, IL-6, and TNF-α provide new insights into T1DM pathogenesis and could be used for screening and diagnosis purposes. They can be also a potential therapeutic target, as well as allowing for more strategies to improve T1DM disease outcomes.Keywords
This publication has 47 references indexed in Scilit:
- The role of cytokines and T-bet, GATA3, ROR-γt, and FOXP3 transcription factors of T cell subsets in the natural clinical progression of Type 1 DiabetesImmunologic Research, 2023
- Decreased expression of miR-150, miR146a and miR424 in type 1 diabetic patients: Association with ongoing islet autoimmunityBiochemical and Biophysical Research Communications, 2018
- Role of miR-34a in TGF-β1- and Drug-Induced Epithelial-Mesenchymal Transition in Alveolar Type II Epithelial CellsJournal of Pharmaceutical Sciences, 2017
- The lack of association between interleukin-6 gene −174 G/C polymorphism and the risk of type 1 diabetes mellitus: A meta-analysis of 18,152 subjectsGene, 2013
- miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular StudyAtherosclerosis, 2011
- Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical studyActa Diabetologica, 2010
- Function of miR-146a in Controlling Treg Cell-Mediated Regulation of Th1 ResponsesCell, 2010
- microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patientsCellular Immunology, 2010
- TGFβ in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T CellsImmunity, 2006
- The Temporal Importance of TNFα Expression in the Development of DiabetesImmunity, 2000